GoodRx Holdings Inc

GoodRx Holdings Inc(GDRX)股票分析

$3.540

-0.078 (-2.21%)收盘时

Loading chart…
最高
3.600
开盘
3.570
成交量加权均价
3.55
成交量
1.14M
市值
2.89B
最低
3.500
成交额
4.04M
企业价值/息税折旧摊销前利润(TTM)
7.89

GoodRx Holdings, Inc. is a platform for medication savings in the United States, used by consumers and healthcare professionals. The Company connects consumers, healthcare professionals, payers, pharmacy benefit managers (PBMs), pharma manufacturers, and retail pharmacies to make saving on medications easier. The Company's offerings include prescription marketplace and pharma manufacturer solutions. Its prescription marketplace consists of its prescription transactions offering and its supplemental subscription and telehealth offerings. Through its GoodRx Care platform, the Company offers consumers access to telehealth visits on a cash-pay basis outside of insurance. The Company partners with pharma manufacturers to advertise and integrate their affordable solutions into its platform. These solutions, provided by pharma manufacturers, include co-pay cards, patient assistance programs, care portals, and other savings options to ensure consumers can access their medications.

AI 分析 of GoodRx Holdings Inc (GDRX)

买入

GoodRx Holdings Inc (GDRX) is a good buy right now at the current price of $3.54, especially considering its forward P/E ratio of 10.29, which suggests it is undervalued compared to its earnings potential. Additionally, the stock has shown a strong year-to-date change of +28.73% and a recent 5-day change of +5.36%, indicating positive momentum. However, the main risk is the decline in net income reported for Q2 2026, which was $8.54 million, down from $12.84 million last year, reflecting potential profitability concerns.

估值指标

GoodRx Holdings Inc(GDRX)当前预期市盈率为 10.29,5 年平均预期市盈率为 35.23。

预期市盈率

合理
5 年均值 P/E
35.23
当前P/E
10.29
高估
643.09
低估
-572.63

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
12.80
当前EV/EBITDA
7.89
高估
24.70
低估
0.89

预期市销率

合理
5 年均值 P/S
3.58
当前P/S
1.48
高估
7.13
低估
0.02

Alphio AI 对 GDRX 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%GDRX

$4.23

情景价格

基

基准

基准 · 50%GDRX

$3.42

情景价格

悲

悲观

悲观 · 25%GDRX

$3.21

情景价格

持有 GDRX 的大户

S

Silver Lake Technology Management, L.L.C.

+ 持有GDRX

+8.71%

3个月收益率

T

TCMI Inc.

+ 持有GDRX

+8.15%

3个月收益率

事件时间线

2026-09-03 (ET)

09:30:00

GoodRx Launches Family Plan for $24.99 Monthly

2026-08-05 (ET)

17:31:00

GoodRx Q2 Revenue $200.4M, Exceeds Consensus

17:30:00

Raises FY26 Adjusted EBITDA Outlook to $240M-$250M

2026-05-27 (ET)

09:10:00

GoodRx Launches GoodRx Companion Subscription at $14.99 per Month

2026-05-06 (ET)

17:10:00

Raises FY26 Adjusted EBITDA Outlook to Over $235M

资讯

GDRX 常见问题 —— 由 Alphio AI 解答

GoodRx Holdings, Inc. is a platform for medication savings in the United States, used by consumers and healthcare professionals. The Company connects consumers, healthcare professionals, payers, pharmacy benefit managers (PBMs), pharma manufacturers, and retail pharmacies to make saving on medications easier. The Company's offerings include prescription marketplace and pharma manufacturer solutions. Its prescription marketplace consists of its prescription transactions offering and its supplemental subscription and telehealth offerings. Through its GoodRx Care platform, the Company offers consumers access to telehealth visits on a cash-pay basis outside of insurance. The Company partners with pharma manufacturers to advertise and integrate their affordable solutions into its platform. These solutions, provided by pharma manufacturers, include co-pay cards, patient assistance programs, care portals, and other savings options to ensure consumers can access their medications. It operates in the Technology sector (SERVICES-COMPUTER PROCESSING & DATA PREPARATION industry).

GoodRx Holdings Inc (GDRX) is a good buy right now at the current price of $3.54, especially considering its forward P/E ratio of 10.29, which suggests it is undervalued compared to its earnings potential. Additionally, the stock has shown a strong year-to-date change of +28.73% and a recent 5-day change of +5.36%, indicating positive momentum. However, the main risk is the decline in net income reported for Q2 2026, which was $8.54 million, down from $12.84 million last year, reflecting potential profitability concerns.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易